Lancet Gastroenterology & Hepatology

Papers
(The H4-Index of Lancet Gastroenterology & Hepatology is 75. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
GORD: pain, PPIs, and preciseness1682
Viral hepatitis: time for action604
Correction to Lancet Gastroenterol Hepatol 2025; 10: 418–30552
Nationwide practice change after early termination of a randomised trial of laparoscopic pancreatoduodenectomy492
The role of ERAS in robotic pancreaticoduodenectomy – Authors' reply471
Lucky: Learning to Live Again452
EASL Congress 2024366
Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study361
Closing the gender gap in gastroenterology leadership: the need for effective and comprehensive allyship343
Treatment withdrawal in Crohn's disease: slowly becoming clearer298
Research in Brief274
Trends in alcohol-specific deaths in the UK and industry responses274
Immune checkpoint inhibitors in colorectal cancer: dream and reality256
Correction to Lancet Gastroenterol Hepatol 2017; 2: 103–11238
Aldafermin in non-alcoholic steatohepatitis: a cautionary tale for trial design233
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma232
Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study229
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled220
Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium208
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension208
A procalcitonin-based algorithm to guide antibiotic use in patients with acute pancreatitis (PROCAP): a single-centre, patient-blinded, randomised controlled trial193
Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial193
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives193
International expert guidance for defining and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound: a consensus statement190
Global multi-stakeholder endorsement of the MAFLD definition182
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept t179
Upfront endoscopic necrosectomy or step-up endoscopic approach for infected necrotising pancreatitis (DESTIN): a single-blinded, multicentre, randomised trial175
ACG 2024174
Long-term VEDOKIDS results: implications for practice and research168
Endoscopist deskilling: an unintended consequence of AI-assisted colonoscopy?161
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised p152
Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial151
Correction to Lancet Gastroenterol Hepatol 2022; 7: 627–47145
Phosphatidylethanol and self-reported alcohol intake to subclassify individuals at risk of steatotic liver disease: an analysis of data from a prospective cohort study144
Availability of point-of-care HBV tests in resource-limited settings143
The pitfalls and promises of scoping reviews in gastroenterology literature – Authors’ reply138
Management of portal vein thrombosis in cirrhosis137
Prevalence of hepatitis C virus seropositivity and active infection in a Rohingya refugee population in Cox's Bazar camps, Bangladesh: a cross-sectional study134
Idiopathic gastroparesis consensus misses the patient's voice133
Research in Brief127
Uptick of food allergies in recent years—real or epiphenomenon?123
Has the time come for a systematic top-down approach in Crohn's disease?119
Combined tumour-infiltrating lymphocytes and microsatellite instability status as prognostic markers in colorectal cancer – Authors' reply119
Resmetirom for NASH: balancing promise and prudence118
Addressing the rise of early-onset colorectal cancer116
Local and systemic therapy in liver cancer: the quest for synergy115
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere114
The potential of ctDNA in locoregional therapies for colorectal cancer112
All roads lead to the gut–brain microbiome network108
The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project)108
Bringing organ preservation closer for selected patients with rectal cancer106
Water and sanitation for all106
Rare cause of dysphagia in a young woman104
Addressing inequities in access to care among Indigenous peoples with chronic hepatitis C in Alberta, Canada104
U-ACTIVATE long-term efficacy and safety outcomes for upadacitinib in ulcerative colitis103
Sex and gender in inflammatory bowel disease outcomes and research102
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study100
Hypovolaemic phlebotomy for hepatic resection98
Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review98
The Year My Life Went Down the Toilet97
Lifting the minority tax in gastroenterology and hepatology97
Management of malignant bowel obstruction – Authors' reply94
A women-focused matrix mentorship programme in gastroenterology94
Early antiviral therapy in adults with moderate to highly viraemic chronic hepatitis B93
Urgent action needed to achieve viral hepatitis elimination91
Dangerous Medicine86
Research in Brief86
The growth of faecal microbiota transplantation in the UK: time for a registry?86
Practicalities accessing precision medicine in biliary tract cancer84
Research in Brief82
Another arrow in the NASH quiver?79
Robotic versus laparoscopic surgery for middle and low rectal cancer77
An unusual complication after a variceal glue injection76
18th Congress of the European Crohn's and Colitis Organisation76
Britta Siegmund: answering the big questions in IBD75
Comprehensive screening for superficial oesophageal squamous cell carcinoma and precancerous lesions75
CEND-1: a game changer for pancreatic cancer chemotherapy?75
0.31587409973145